BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC

BeyondSpring Inc.

Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.
Plinabulin Phase 3 data published in Lancet Respiratory Medicine: statistically significant overall survival benefit in 2L/3L NSCLC EGFR wild-type vs docetaxel.
Agreement to sell portion of SEED shares for ~$35.4M gross proceeds; first close of $7.35M in Feb 2025.
SEED entered Eisai research collaboration with potential payments up to $1.5B; completed $24M Series A-3 first close led by Eisai.
SEED's RBM39 degrader ST-01156 granted Rare Pediatric Disease and Orphan Drug Designations by FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.